申请人:MERRELL PHARMACEUTICALS INC.
公开号:EP0518767A2
公开(公告)日:1992-12-16
This invention relates to novel amide derivatives of certain 2,6-methano-2H-quinolizine-type compounds, to the intermediates and processes for their preparation, to their ability to induce a blockage of 5HT3 receptors, and to their end-use application in the treatment of chemotherapeutically-induced nausea and vomiting, as anti-anxiety agents, in the symptomatic treatment of pain associated with migraine, as anti-arrhythmic agents, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia, and mania, in the treatment of glaucoma, for stimulating gastric motility, to combat drug abuse, to treat sleep apnea and to treat irritable bowel syndrome.
本发明涉及某些 2,6-甲桥-2H-喹嗪类化合物的新型酰胺衍生物、制备它们的中间体和工艺、它们诱导阻断 5HT3 受体的能力,以及它们在治疗化疗引起的恶心和呕吐、作为抗焦虑药的最终应用、对偏头痛相关疼痛的对症治疗、作为抗心律失常药物、治疗认知障碍、治疗精神分裂症和躁狂症患者表现出的幻觉性内源性精神病、治疗青光眼、刺激胃肠蠕动、打击药物滥用、治疗睡眠呼吸暂停和治疗肠易激综合征。